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CAnti-rejection regimens for renal transplants have changed dramati-
cally during the past 20 years, but there are few long-term studies
relating cost,mortality, or graft failure simultaneously to disease-phar-
macotherapy couplets. We analyzed US Renal Data System data on a
matched-pair cohort of first, single organ kidney transplants from 1998
through 2002 over up to 5 years following transplantation for patients
on tacrolimus or low-dose cyclosporine, stratifying by whether the re-
cipient had pre-existing or new onset diabetes. Kaplan-Meier survival O
essor
al So
doi:10.1016/j.jval.2010.10.030urves show mortality and survival differences associated with diabe-
es, but no additional incremental effects of immune suppression reg-
men. Significant cost increases are reported for patients receiving ta-
rolimus above and beyond the extra costs associated with diabetes.
eywords: diabetes, long-term costs, long-term effects, renal trans-
lantation, pharmacoeconomics.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Diabetes mellitus (DM) is a serious chronic disease that is asso-
ciated both with greater morbidity and earlier mortality [1–7]
and higher medical expenses among kidney transplant recipi-
ents [5,8]. Large, recent, international, randomized clinical tri-
als comparing tacrolimus (FK)-based immunosuppression (IS)
regimens to low-dose cyclosporine (CsA)-based IS in renal
transplantation report fewer rejection episodes among patients
on FK compared to CsA, but significantly higher incidence of
new onset DM after transplant (NODAT) [9–11]. Additional pub-
lications [3–6,9,12–17] confirm the NODAT result. Also favoring
CsA, patients who received deceased-donor organs and who
were treated with FK-based regimens appeared to be more ex-
pensive [5]. Yet despite the differences in rejection episodes and
NODAT, no significant differences in graft and patient survival
are reported between patients treated with CsA and FK at both 6
months [10] and at 12 months [11,14,18] post-transplant.
To estimate the longer-term outcome and cost implications of
diabetes and the alternative calcineurin-based IS regimens that
may increase the risk of diabetes, this study examines Medicare’s
costs and patient- and graft-survival for three groups of patients,
those with pre-existing diabetes at transplantation (pre-DM),
those who develop NODAT, and those who have shown no sign of
DM either before or after transplant (never DM). Despite the short-
comings of registry and claims data, they are capable of providing
longer-term estimates of survival and costs than are possible with
clinical trials.
* Address correspondence to: Robert S. Woodward, McKerley Prof
E-mail address: rsw@unh.edu.
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Published by Elsevier Inc.Materials and Methods
Data
We used data from the US Renal Data System, which is a joint effort
between theNational Institute of Diabetes andDigestive and Kidney
Diseases, and the Centers for Medicare and Medicaid Services [19].
Our sample initially contained all 142,976 first, kidney-only trans-
plants between January 1, 1995, and December 31, 2005. But because
the number of transplant patients receiving FK versus CsA crossed
into the majority around the year 2000 (Fig. 1) we selected a period
before andafter the crossoverwith sufficient observations to support
multivariate and subgroup analyses. Specifically, we focused on the
59,756 transplants performed on or after January 1, 1998, and on or
before December 31, 2002. From these, we further limited our atten-
tion to the 49,858 individuals whose initial maintenance IS regimen
was based on either FK or CsA, but not both. As an analysis of treat-
ment intentions, we did not track subsequent regimen changes.
To compare costs, we then selected the 24,816 observations
where Medicare was considered the primary payer, defined as fol-
lows: a patient must have accumulated $7500 or more in any Medi-
care institutional claims (IC)within thefirst year post-transplant and
$1000 or more in any Medicare physician-supplier claims (PSC)
within the first year post-transplant. We explored different thresh-
olds such as $5000 in IC and $50 in PSC but our results were largely
unchanged.
Finally and because we observed significant IS-regimen-related
differences in race, sex, peakpanel reactive antibodies (PRA), and the
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444 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 4 3 – 4 4 9number of human leukocyte antigen (HLA) mismatches among the
sample of 24,816, we further winnowed the data by constructing a
matched-pair subsample where an equal number of observations
were selected in the groups defined by the combination of donor
type (cadaveric or living), age groups (younger than 20 years,
20–29 years, 30–39 years, 40–44 years, 45–49 years, 50–54 years,
55–59 years, 60–65 years, 66–69 years, and 70 years or older),
recipient’s race (white, black, or other), recipient’s sex, peak
PRA (greater than 10 or less than or equal to 10), and HLA mis-
matches (zero to six). Based on selections without replacement,
we were able to define 10,259 matched pairs for a total of 20,518
observations.
Diabetes definitions
We adopted a commonly used method for determining diabetes
status [20]. International Classification of Diseases codes within
the range between 250.00 and 250.79 were used to identify claims
relating to DM. Patients were considered as diabetic before trans-
plantation (Pre-DM) whenever either 1) the patient had one or
more DM-related ICs or two or more PSCs before transplant; or 2)
the US Renal Data System indicated that the patient had DM at the
time of transplant (DIABR). Patients without DM at transplant,
whether or not they developed it after transplant, were de-
scribed as “No Pre-DM.” NODAT was defined for patients with-
out diabetes before transplant if the patient had one or more ICs
or two or more PSCs within the 3 years after transplant. Patients
were classified as No-DM if no diabetes was reported either
before or after transplantation.
Censoring
Patients were censored before transplantation (left censored) at
the time of their first claim or 1095 days, whichever was closest to
Table 1a – Differences in pre-existing diabetes mellitus
(DM) by calcineurin inhibitor (tacrolimus [FK] or
low-dose cyclosporine [CsA]).
Total Pre DM No Pre
DM
Significance
test
Observations 20,518 9530 10,988
FK 50.00% 48.10% 51.90% 2  22.65
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Fig. 1 – Number of initial calcineurin inhibitor
immunosuppressant regimens for tacrolimus (FK)
and low-dose cyclosporine (CsA).P  0.0001CsA 50.00% 44.79% 55.21%the transplant date. After transplantation, all patients were cen-
sored at the lost-to-follow-up date, the end of available data, the
date of their last claim, or 1825 days, whichever came first. Graft
failure and cost analyses added censoring at death date. Days
without DM added censoring at the date of graft failure. In this
censoring-based patient enlistment, there were no minimum pe-
riods of observation either pre- or post-transplant.
Analyses
We used Kaplan-Meier plots to analyze the differences in patient
and graft survival as well as in days survival without DM.We used
the log-rank test to determine the significance of the differences.
We computed daily average accumulated Medicare pay-
ments (AAMPs) per patient for the 3 years before and the 5 years
after transplant. The plots of the AAMPs are adjusted to pass
through the origin of the cost (vertical axis) and the transplant
date (horizontal axis). To facilitate comparisons between the
slopes of the cost curves before and after transplantation, the
costs before transplantation are drawn down and to the left of
the origin. The AAMPs on any given day represents the AAMPs
from the previous day plus the average incremental cost on that
day for uncensored individuals [5]. Claims were adjusted to 2002
dollars with the Medical Care Services component of the Con-
sumer Price Index. Bootstrapping, a repeated sampling tech-
nique [21] with 1000 iterations, was used to test for significant
Fig. 2 – Survival without diabetes mellitus (DM), by
calcineurin inhibitor (no pre-DM, death, and graft failure
Table 1b – Differences in new onset diabetes after
transplant (NODAT) by calcineurin inhibitor (tacrolimus
[FK] or low-dose cyclosporine [CsA]).
Total FK CsA Significance
test
Observations with no
pre-existing
diabetes
10,988 5324 5664
Never diabetes 62.32% 56.89% 67.43% 2  129.65
P  0.0001NODAT during 3
years
37.67% 43.11% 32.57%
Observations with
NODAT during 3
years post-
transplant
4140 2295 1845
NODAT during
year 1
69.59% 73.07% 65.26% 2  29.51
P  0.0001
NODAT during
years 2 and 3
30.41% 26.93% 34.74%censored, 1998–2002 transplants).
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445V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 4 3 – 4 4 9differences in the non-parametric AAMPs at 3 and 5 years post-
transplant.
All data manipulation and statistical analyses used SAS, ver-
sion 9.1 (SAS Institute Inc., Cary, NC).
Results
Descriptive statistics
Pre-existing DM
Because of the matched-pair method, there were exactly 10,259
patients each with IS regimens based on FK and CsA. Neverthe-
less, significantly greater proportion of FK patients had pre-exist-
ing DM (48.1% vs. 44.8%, P  0.0001) (Table 1a).
NODAT
Among patients without pre-DM, NODAT occurred during the
first 3 years post-transplant more frequently among FK patients
(43.1%) than among CsA patients (32.6%) (P  0.0001, Table 1b).
Most of the NODAT occurred within the first year post-trans-
plant for both IS regimens, but a higher proportion of the
NODAT among FK patients occurred during the first post-trans-
plant year (73.1% of FK NODAT vs. 65.3% of CsA NODAT) (P 
.0001, Table 1b).
The IS-related difference in DM incidence is graphically pre-
ented by a Kaplan-Meier plot of days survival without diabetes
Fig. 2). When patients are comprehensively censored, including
or death and graft failure, the Kaplan-Meier analysis reports
Table 2 – Mean age with Tukey grouping by calcineurin
inhibitor immunosuppression regimen (tacrolimus [FK]
or low-dose cyclosporine [CsA]) and diabetes mellitus
(DM) cohort (pre-existing diabetes [Pre-DM], new onset
diabetes after transplant [NODAT], or no DM).
Observations Mean
age
Tukey
group
FK 10,259 48.06 A
CsA 10,259 48.02 A
Pre-DM - CsA 4595 51.9 B
Pre-DM - FK 4935 51.6 B
NODAT - CsA 1845 48.9 C
NODAT - FK 2295 48.6 C
No-DM - CsA 3819 43.1 D
No-DM - FK 3029 41.8 E
Note: Mean ages within the same Tukey group are not significantly
different,   0.05. Mean ages in different Tukey groups are signif-
icantly different,   0.05.
Table 4 – Differences in diabetes mellitus (DM) status amon
calcineurin inhibitor (tacrolimus [FK] or low-dose cyclospo
Total
African Americans without Pre-DM
Observations 3161
No-DM 56.79%
New onset diabetes during 3 y after transplant 43.21%
Whites without Pre-DM
Observations 7335
No-DM 64.80%
New onset diabetes during 3 y after transplant 35.20%that 56.77% of FK patients and 67.31% of CsA patients (P 
0.0001) survived 3 years without diabetes.
Age
Although there were no significant age differences between the
overall FK and CsA cohorts, there were significant age differences
between the diabetes groups (Table 2). Patients with Pre-DM were
approximately 3 years older than patients with NODAT, who in
turn were approximately 6 years older than patients with No-DM,
P  0.05. Only among patients who never developed diabetes (No-
DM)were FK patients significantly younger than CsA patients, 41.8
years versus 43.1 years, respectively, P  0.05.
Race, sex, donor type, peak PRA, and HLA mismatches
The sample was predominantly white with only 28.8% African
American and 4.6% other races (Table 3). The sample was also
predominantly male (60.3%), received predominantly deceased-
donor organs (74.4%), had an average of 3.8 HLA mismatches, and
only 17.7%with peak PRAmore than 10%. Because all these factors
were used in the matched-pair selection process, there were no
differences in these values between FK and CsA.
Cytomegalovirus (CMV) serology
CMV serology was not used as a match criterion. Among pa-
tients on FK, 60.85% were CMV positive versus 61.18% of pa-
tients on CsA, P  0.6467. A slightly higher proportion of CsA
atients (60.3% vs. 58.1% for FK patients, P  0.0013) received
heir transplant from a CMV positive donor. But this difference
as not considered important in these analyses.
Race and IS regimens are known determinants of the suscep-
ibility to DM. Beyond that, the use of FK among whites in-
reased the 3-year incidence of DM by 9.25%, whereas the in-
rease among African Americans was 12.95% (Table 4). In
ontrast, the use of FK was not associated with any greater
Table 3 – Descriptive statistics.
Total
Observations 20,518
Proportion African American
Proportion white
Proportion other
28.76%
66.59%
4.65%
Proportion men
Proportion women
60.28%
39.72%
Proportion living donor
Proportion deceased donor
25.60%
74.40%
Proportion recipient cytomegalovirus positive 61.01%
Proportion donor cytomegalovirus positive 69.15%
Proportion peak panel reactive antibody  10 17.68%
Mean number of human leukocyte antigen mismatches 3.776
cipients without DM before transplant, by race and
[CsA]).
FK CsA Significance test
1536 1625
50.13% 63.08% P  0.0001
49.87% 36.92%
3553 3782
60.03% 69.28% P  0.0001g re
rine39.97% 30.72%
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Nor was the use of FK associated with any greater NODAT
among recipients of deceased donor organs than among recip-
ients of living donor organs (Table 6).
Patient and graft survival
Whether DM had developed before transplantation or devel-
oped within 3 years after transplantation, it significantly re-
duced patient survival. At 2 years post-transplant, patients with
no DM and patients with NODAT had roughly the same graft
survival at 94.2% and 94.8%, respectively (Fig. 3). In contrast, at
2 years post-transplant, the survival among patients with pre-
existing DM was only 89.4%. But by 5 years, survival among
NODAT patients (79.3%) was substantially less than survival
among patients without diabetes (86.3%), and the survival of
patients with pre-existing DM had fallen to 71.2% (P  0.0001).
In contrast, the death-censored graft survival rates were al-
most identical over the full 5 years post-transplant among the
patients who had pre-existing DM at transplantation (80.8%)
and among those who never developed DM (80.9%) (Fig. 4). But
NODAT did significantly reduce graft survival at 5 years to 77.2%
(P  0.0001).
Because FK is associated with an increased risk of NODAT
and because NODAT is associated with lower patient and graft
survival, we expected to find that FK was associated with sig-
nificantly poorer patient and/or graft survival. But in this
matched-pair sample, no such association was found among
any of the logical groups. In particular, there were no significant
IS-regimen associated differences in patient or graft survival
(death censored or not) among patients in any of our defined
groups: those with or without pre-existing DM, those who de-
veloped NODAT, or those who never developed DM.
Medicare payments
DM was expensive, both before and after transplantation. Be-
fore transplantation, the AAMPs showed significant differences
only between patients with and without diabetes (Fig. 5). During
Table 6 – Differences in diabetes mellitus (DM) status amon
source and calcineurin inhibitor (tacrolimus [FK] or low-do
Total
Deceased donors with no pre-DM
Observations 7968
No DM 60.39%
New onset DM during 3 y after transplant 39.61%
Living donor with no pre-DM
Observations 3020
No DM 67.42%
Table 5 – Differences in diabetes mellitus (DM) status amon
calcineurin inhibitor (tacrolimus [FK] or low-dose cyclospo
Total
Women with no pre-DM
Observations 4489
No DM 62.73%
New onset DM during 3 y after transplant 37.27%
Men with no pre-DM
Observations 6499
No DM 62.04%
New onset DM during 3 y after transplant 37.96%New onset DM during 3 y after transplant 32.58%the 3 years before transplantation, Medicare paid approxi-
mately $20,085 more for patients with DM (P  0.05). By 5 years
after transplantation, Medicare had spent $162,048 on patients
with pre-existing DM, $146,915 on patients who developed
NODAT, and only $114,686 on patients who never developed
DM. Both the $15,133 and the $32,229 differences were signifi-
cant at a 5% level.
Pretransplant, tacrolimus patients were no more expensive
than CsA patients (Fig. 6). But by 5 years post-transplant, Medi-
care had paid on average a total of $8341 more for tacrolimus
patients with no pre-existing DM than for similar CsA patients
and an extra $6929 for tacrolimus patients who had pre-existing
DM (P  0.05).
Figure 7 provides some insight into the question about
whether the differences observed in Figure 6 were attributable
to the costs of the drugs themselves, were related to the higher
proportion of tacrolimus patients who develop NODAT, or
might have been caused by higher costs of therapies treating
NODAT among FK patients. As previously, the pre-transplanta-
tion costs of all four groups were equivalent. Moreover, the IS
regimen costs were equivalent among patients who never de-
veloped DM. But by 5 years post-transplant, the average Medi-
care payments for patients who developed NODAT were almost
$15,000 greater for patients with a tacrolimus-based regimen
than they were for patients with a CsA-based regimen, P  0.05.
Discussion
We explored the clinical efficacy and costs associated with DM
among first kidney transplant recipients during an epoch when
FK and CsA had roughly similar application and roughly equiv-
alent shares of the maintenance IS market. One purpose was to
document the long-term patient and graft survival and the fi-
nancial costs associated with DM pre- and post-transplant. An-
other was to identify any net advantage associated with the use
of one or the other IS regimen. To do so, we constructed a
match-pair cohort of 20,518 transplants between 1998 and 2002.
cipients without DM before transplant (pre-DM), by donor
closporine [CsA]).
FK CsA Significance test
3878 4090
54.87% 65.62% P  0.0001
45.13% 34.38%
1446 1574
62.31% 72.11% P  0.0001
cipients without DM before transplant, by sex and
[CsA]).
FK CsA Significance test
2887 2683
57.31% 67.82% P  0.0001
42.69% 32.18%
3721 4034
56.60% 67.15% P  0.0001
43.40% 32.85%g re
se cyg re
rine37.69% 27.89%
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447V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 4 3 – 4 4 9Outcomes included Kaplan-Meier analyses of patient and graft
survival. Cost results were derived from comparisons of AAMPs
from a period of 3 years before to 5 years after transplant.
Although the negative influence of diabetes on patient and
graft survival is well known, the pattern presented by our Kaplan-
Meier plots may be less well reported. The plot of patient survival
by DM status, Figure 3, shows no patient-survival difference at 2
ears post-transplant between patients who never developed DM
nd patients who developed NODAT. That observation is consis-
ent with the hypothesis that there is at least a 2-year lag before
M starts affecting patient survival.
Also surprising was the lack of any death censored graft failure
ifference between patients who never developed DM and patients
ransplanted with pre-existing DM. One might speculate that the
quivalence is consistent with the hypothesis that transplant neph-
ologistswhoknowabout a patient’s diabetes are able tomanage the
raft to eliminate any diabetes-related hazard. As expected, we
ound a greater graft failure among patients with NODAT.
It was not surprising to find that DM increased Medicare pay-
ents, both before and after transplantation. It was of some inter-
st to note that Medicare’s post-transplant payments for patients
Fig. 3 – Patient survival by diabetes mellitus (DM) status:
new onset DM after transplant (NODAT), never DM, or
pre-existing DM (pre-DM) before transplant.
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Fig. 5 – Average accumulative Medicare payments (AAMPs)
any DM, or new onset DM after transplant (NODAT).ith pre-existing DM were significantly greater than their pay-
ents for patients with NODAT.
It was surprising to observe that patients on FK-based IS
egimens required significantly greater Medicare payments,
hether or not those patients had pre-existing DM. Further
nalysis revealed that the extra costs were not observed in pa-
ients who never developed DM. The implication, then, is that
he extra Medicare payments made on behalf of patients with
K-based IS regimens were related to the costs of DM-related
herapies and not to cost of the IS regimens themselves.
One limitation of this study was its dependence on retrospec-
ive registry and claims data. Although these data provided large
umbers of observations, we based our analyses on a match-pair
ohort of patients, and while we further divided the cohort into
ubgroups for diabetic and calcineurin inhibitor (CNI) subgroups
n all of our analyses, these are weaker controls for equivalence
han randomization.
Our analysis has several strengths when compared to previ-
us clinical trials. We were able to select patients during years
Fig. 4 – Kaplan-Meier graft survival by diabetes mellitus
(DM) status: new onset DM after transplant (NODAT), never
DM, or pre-existing DM (pre-DM) before transplant. Based
on data from 1998-2002, death censored.
365 730 1,095 1,460 1,825
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able to track them pre-transplantation and to follow them for a
longer period of analysis after transplantation. Other studies
have not typically examined patient records for either costs or
DM diagnoses during the 3 years before transplantation nor
tracked survival or costs for 5 years post-transplant.
We have previously analyzed the effect of choice of CNI on
outcomes and costs but this was during an era when the pre-
dominant maintenance CNI was CsA and not FK and trough
levels for both CNIs were much higher than what are currently
used in clinical practice [5]. This analysis extended our prior
observations from a shorter 2-year follow-up analysis to a
5-year analysis and in a more contemporaneous era. Here, we
have shown that higher NODAT significantly affects patient and
Fig. 6 – Average accumulative Medicare payments (AAMPs)
cyclosporine) for all patients in the study. DM, diabetes mell
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cyclosporine), for no pre-existing diabetes mellitus (DM) patientsgraft survival by 5 years post-transplant. The 5-year findings are
important and clinically significant because one normally ex-
pects the poor outcomes associated with DM to occur after more
than 10 to 15 years, not within the time frame of this study.
We also have concluded that the IS regimen had no net effect
on patient or graft survival. This is surprising given the higher
incidence of NODAT and its detrimental impact on patient and
graft survival. Although it may be that the disadvantages of the
higher incidence of NODAT among FK patientsmay offset by the
advantage of a lower incidence of acute rejection episodes, such
a determination is beyond the scope of this research. We leave
it to future research to compare directly the effects of the higher
incidence of DM among FK patients with the effects of the
higher incidence of acute rejections among CsA patients.
munosuppression regimen (tacrolimus or low-dose
730 1,095 1,460 1,825
ransplant
Tacrolimus NODAT Tacrolimus No DM
munosuppression regimen (tacrolimus or low-doseby im
itus.365
om T
No DM
by im
. NODAT, new onset diabetes mellitus after transplant.
[[
[
[
[
[
[
[
[
[
[
449V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 4 3 – 4 4 9Our analyses also confirmed our previous conclusions about
the higher costs incurred by patients with FK-based IS regi-
ments. First, pre-DM patients incurred greater medical ex-
penses than NODAT patients, who in turn incurred greater
medical expenses than patients who never develop DM. More
significantly, FK patients had higher medical expenses than do
CsA patients within both of the groups (pre-DM and NODAT).
Source of financial support: A grant fromNovartis Pharma, LLC,
to the University of New Hampshire.
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